Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
Robert Hans Ingemar Andtbacka(University of Utah), Kenneth F. Grossmann(University of Utah), Adil Daud(Memorial Sloan Kettering Cancer Center), Matthew H. Taylor(Providence Portland Medical Center), Rogerio I. Neves(Saint John's Health Center), John T. Vetto(Oregon Health & Science University), Richard S. Ungerleider(Theradex Oncology (United States)), Merrick I. Ross(The University of Texas MD Anderson Cancer Center), Sanjiv S. Agarwala(Goethe University Frankfurt), Maki Tanaka(Takara (Japan)), Hung T. Khong(University of Utah)
Cited by 55
Related Papers
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|1999|763